ALGS Q1 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$311,000-68.5% YoY

Gross Profit

$311,000100.0% margin

Operating Income

-$19M-6187.5% margin

Net Income

$43M13854.7% margin

EPS (Diluted)

$-2.11

QoQ Revenue Growth

-50.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$959,000

Balance Sheet

Total Assets

$151M

Total Liabilities

$34M

Stockholders' Equity

$116M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$311,000	$986,000	-68.5%
Gross Profit	$311,000	$986,000	-68.5%
Operating Income	-$19M	-$22M	+12.7%
Net Income	$43M	-$35M	+223.6%